The immune system's reaction to the common Epstein-Barr virus can ultimately damage the brain and contribute to multiple ...

Our results provide mechanistic evidence that immune responses to EBV can directly damage the brain in MS,” said Olivia Thomas, PhD, assistant professor at the Department of Clinical Neuroscience at ...

In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

The immune system's reaction to the common Epstein-Barr virus can ultimately damage the brain and contribute to multiple sclerosis (MS). This is shown ...

The BLA was resubmitted in 2025, after Atara and the FDA aligned on the criteria and addressed the initial CRL conditions.

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...

The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.

Recent findings suggest that the Epstein-Barr virus (EBV) is involved in both causing multiple sclerosis (MS) and shaping its ...

One of the leading triggers for multiple sclerosis (MS) is an infection with the Epstein-Barr virus. However, certain gene variants also play an important role.

A second complete response letter issued by the U.S. FDA for Atara Biotherapeutics Inc.’s allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) for Epstein-Barr virus positive post-transplant ...

We’ve written plenty of editorials on health care over the past couple years. But there’s a major area of health we haven’t ...